中止
医学
乙型肝炎表面抗原
内科学
预测值
生物标志物
肿瘤科
乙型肝炎
慢性肝炎
免疫学
试验预测值
抗病毒治疗
丙型肝炎
抗原
肝炎
实时聚合酶链反应
病毒载量
回顾性队列研究
共病
作者
Lin Mei Yao,Chuan Chun Mao,Yuan Tian,Yao Lu,Lu Zhang,Ge Shen,Shu Ling Wu,Min Chang,Hong Xiao Hao,Lei Ping Hu,Yuan Jiao Gao,Meng Jiao Xu,Yao Xie,Ming Hui Li,Ru Yu Liu
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-10-20
卷期号:39 (10): 1215-1224
摘要
Objective: Serum markers predicting virologic relapse after pegylated interferon-alpha (Peg-IFN-α) discontinuation in patients with chronic hepatitis B (CHB) are lacking. This study aimed to evaluate serum pregenomic RNA (pgRNA), hepatitis B core-related antigen (HBcrAg), and hepatitis B surface antigen (HBsAg) as potential predictors of Peg-IFN-α treatment outcomes and post-treatment virologic relapse in treatment-naïve patients with CHB. Methods: A total of 371 treatment-naïve patients with CHB were initially recruited for this study, and 327 patients who completed the entire follow-up period were included in the data analysis. Serum pgRNA and HBcrAg levels were measured by polymerase chain reaction (PCR)-fluorescence probing and enzyme-linked immunosorbent assay (ELISA), respectively. Results: , 0.356) levels correlated with treatment efficacy, demonstrating predictive values with AUCs of 0.821, 0.879, and 0.781, respectively. HBcrAg levels at treatment discontinuation were associated with virologic relapse and showed potential as predictive biomarkers (AUC, 0.790). Conclusion: Serum pgRNA, HBcrAg, and HBsAg correlate with Peg-IFN-α response in treatment-naïve CHB. Serum HBcrAg levels at Peg-IFN-α discontinuation show potential as a predictive biomarker for post-treatment virologic relapse and are associated with relapse risk, which may help identify high-risk patients after Peg-IFN-α cessation. Notably, this finding requires further validation in larger cohorts due to the limited number of relapse events.
科研通智能强力驱动
Strongly Powered by AbleSci AI